Cargando…

Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients

Studies describing SARS-CoV-2 immune responses following mRNA vaccination in hematology malignancy (HM) patients are virtually non-existent. We measured SARS-CoV-2 IgG production in 67 HM patients who received 2 mRNA vaccine doses. We found that 46% of HM patients did not produce antibodies and were...

Descripción completa

Detalles Bibliográficos
Autores principales:	Agha, Mounzer, Blake, Maggie, Chilleo, Charles, Wells, Alan, Haidar, Ghady
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8043479/ https://www.ncbi.nlm.nih.gov/pubmed/33851182 http://dx.doi.org/10.1101/2021.04.06.21254949

Ejemplares similares

Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking Era
por: Agha, Mounzer E, et al.
Publicado: (2021)

1600P Suboptimal response to COVID-19 mRNA vaccines in older patients with cancer
por: Landre, T., et al.
Publicado: (2021)

Anti-spike T-cell and Antibody Responses to SARS-CoV-2 mRNA Vaccines in Patients with Hematologic Malignancies
por: Greenberger, Lee M., et al.
Publicado: (2022)

Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies
por: Jiménez, Moraima, et al.
Publicado: (2022)

Hematologic Malignancies Diagnosed in the Context of the mRNA COVID-19 Vaccination Campaign: A Report of Two Cases
por: Zamfir, Maria-Alexandra, et al.
Publicado: (2022)

1105. The Burden of Infections Prior to Chimeric Antigen Receptor (CAR) Modified T-cell Therapy Predicts Post-CAR T-cell Infectious Complications
por: Garner, Will, et al.
Publicado: (2020)

The humoral response of mRNA COVID-19 vaccine in hematological diseases: The HEMVACO study
por: Gueguen, M., et al.
Publicado: (2022)

Efficacy and safety profile of COVID-19 mRNA vaccine in patients with hematological malignancies: Systematic review and meta-analysis
por: Rinaldi, Ikhwan, et al.
Publicado: (2022)

Seroconversion to mRNA SARS-CoV-2 Vaccines in Hematologic Patients
por: Fattizzo, Bruno, et al.
Publicado: (2022)

Serological and cellular response to mRNA-SARS-CoV2 vaccine in patients with hematological lymphoid malignancies: Results of the study “Cervax”
por: Mohamed, Sara, et al.
Publicado: (2023)

202. The Impact and Safety of Discontinuing Routine Surveillance Blood Culture Monitoring in Allogeneic Hematopoietic Cell Transplant Recipients
por: Garner, Will, et al.
Publicado: (2021)

Antibody Response to COVID-19 mRNA Vaccines in Oncologic and Hematologic Patients Undergoing Chemotherapy
por: Mencoboni, Manlio, et al.
Publicado: (2022)

Can Individuals with Suboptimal Antibody Responses to Conventional Antiviral Vaccines Acquire Adequate Antibodies from SARS-CoV-2 mRNA Vaccination?
por: Ogura, Wataru, et al.
Publicado: (2022)

Autoimmune Hematologic Disorders in Two Patients After mRNA COVID-19 Vaccine
por: Gaignard, Marie-Estelle, et al.
Publicado: (2021)

Clinical and immunological effects of mRNA vaccines in malignant diseases
por: Heine, Annkristin, et al.
Publicado: (2021)

Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients
por: Haggenburg, Sabine, et al.
Publicado: (2022)

Evaluation of serological response to anti-SARS-CoV-2 mRNA vaccination in hematological patients
por: Pascale, Sara Pasquina, et al.
Publicado: (2022)

Blunted humoral response after mRNA vaccine in patients with haematological malignancies
por: Kamboj, Mini
Publicado: (2021)

Immunity to a third BNT162B2 COVID-19 vaccine after heart transplantation: Bridging the knowledge gap to end the pandemic for organ transplant recipients
por: Haidar, Ghady
Publicado: (2022)

Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects
por: Wheeler, Sarah E., et al.
Publicado: (2021)

Suboptimal antibody response against SARS-CoV-2 Omicron variant after third dose of mRNA vaccine in kidney transplant recipients
por: Al Jurdi, Ayman, et al.
Publicado: (2022)

Activity of mRNA COVID-19 vaccines in patients with lymphoid malignancies
por: Crombie, Jennifer L., et al.
Publicado: (2021)

mRNA as a Therapeutics: Understanding mRNA Vaccines
por: Oğuz, Ferdi, et al.
Publicado: (2022)

mRNA Vaccine Platform: mRNA Production and Delivery
por: Litvinova, V. R., et al.
Publicado: (2023)

OAB-048: Suboptimal humoral immune response to SARS-CoV-2 mRNA vaccination in myeloma patients is associated with anti-CD38 mAb and BCMA-targeted treatment
por: Oekelen, Oliver Van, et al.
Publicado: (2021)

Humoral response to mRNA‐based COVID‐19 vaccine in patients with myeloid malignancies
por: Mori, Akio, et al.
Publicado: (2022)

HIV and Messenger RNA (mRNA) Vaccine
por: Khalid, Khizer, et al.
Publicado: (2021)

Correlation between BNT162b2 mRNA Covid-19 vaccine-associated hypermetabolic lymphadenopathy and humoral immunity in patients with hematologic malignancy
por: Cohen, Dan, et al.
Publicado: (2021)

Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine
por: Palumbo, Giuseppe A., et al.
Publicado: (2023)

586. Immunogenicity of COVID-19 mRNA Vaccines in Patients with Lymphoid Malignancies
por: Izaguirre, Natalie E, et al.
Publicado: (2021)

Dangers of mRNA vaccines
por: Ali, Tahoora, et al.
Publicado: (2021)

mRNA-Based Vaccines
por: Kowalzik, Frank, et al.
Publicado: (2021)

Advances in mRNA vaccines
por: Li, Mengyun, et al.
Publicado: (2022)

Quantitative Effect of Suboptimal Codon Usage on Translational Efficiency of mRNA Encoding HIV-1 gag in Intact T Cells
por: Ngumbela, Kholiswa C., et al.
Publicado: (2008)

Reduced Antibodies and Innate Cytokine Changes in SARS-CoV-2 BNT162b2 mRNA Vaccinated Transplant Patients With Hematological Malignancies
por: Bergamaschi, Cristina, et al.
Publicado: (2022)

A graveyard for mRNA
por: Wells, William A.
Publicado: (2003)

mRNA vaccines: the most recent clinical applications of synthetic mRNA
por: Kwon, Suji, et al.
Publicado: (2022)

Myocarditis following COVID‐19 mRNA (mRNA‐1273) vaccination
por: Chellapandian, Suresh Babu, et al.
Publicado: (2022)

Antibody responses to mRNA versus non-mRNA COVID vaccines among the Mongolian population
por: Sereejav, Enkhbold, et al.
Publicado: (2023)

Immunogenicity of Sars-Cov-2 mRNA 1273 Vaccine in Patients with Lymphoid Malignancies
por: Dong, Ning, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_d0i6dnldlrm0l42f5inm51jsp4